Please assess the completion status of the following clinical trial:

Trial Title: Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be diagnosed as stable CHD, and must have at least one of these histories:~  1. A history of coronary revascularization Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Surgery at least 3 months ago~ 2. Myocardial infarction~ 3. More than 50 percent (%) stenosis detected by angiography~ 4. Exercise Tolerance Testing (ETT) or Computed Tomography Angiography (CTA) showed more than 50% stenosis with typical angina symptoms~* Subjects must have at least 2 times of typical symptoms of myocardial ischemia occurred within a week Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Coronary syndrome or considering acute coronary syndrome (ACS)~* Left main coronary artery disease without revascularization~* Aortic stenosis~* Obstructive hypertrophic cardiomyopathy~* Subjects with hypertension systolic blood pressure (SBP) greater than (\>) 170 millimeters of mercury (mmHg) or diastolic blood pressure (DBP) \>100 mmHg) or hypotension (SBP less than \[\<\] 90 mmHg or DBP\<60 mmHg)~* Diagnosis as postural hypotension before~* Congestive heart failure (New York Heart Association \[NYHA\] class III - IV~* Ejection fraction (EF)\<40% by Echocardiography~* Arrhythmias requiring active treatment~* Gastro-intestinal ulcer~* Concomitant medication such as Sulphonyl urea, PDE-5 inhibitor such as sildenafil, Trimetazidine for treatment of angina pectoris Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment plus nicorandil (Type: EXPERIMENTAL): The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors \[(ACEIs\] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
- Standard treatment (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).